Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$13.89 +3.1%	$14.15	$9.57 ▼ $30.41	$1.91B	0.99	1.45 million shs	1.67 million shs
CNTA Centessa Pharmaceuticals	$13.71 -0.1%	$14.26	$7.75 ▼ $19.09	$1.83B	1.53	610,862 shs	553,595 shs
DNA Ginkgo Bioworks	$7.37 -0.1%	$7.38	$5.00 ▼ $41.20	$428.29M	1.34	1.48 million shs	1.24 million shs
GLPG Galapagos	$26.92	$25.40	$22.36 ▼ $31.23	$1.77B	0.16	211,461 shs	485,135 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	+3.12%	+6.76%	+9.03%	-31.34%	-38.59%
CNTA Centessa Pharmaceuticals	-0.07%	+5.22%	-4.66%	-18.92%	+49.67%
DNA Ginkgo Bioworks	0.00%	-2.90%	+29.18%	-46.73%	-79.32%
GLPG Galapagos	0.00%	+5.57%	+7.17%	+16.99%	-5.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.6152 of 5 stars	3.3	1.0	3.4	3.7	2.5	0.0
CNTA Centessa Pharmaceuticals	2.5563 of 5 stars	3.5	1.0	0.0	2.9	3.3	0.6
DNA Ginkgo Bioworks	0.5641 of 5 stars	0.8	1.0	0.0	1.3	2.5	1.3
GLPG Galapagos	0.5924 of 5 stars	0.8	4.0	0.0	2.4	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.60	Moderate Buy	$41.44	198.38% Upside
CNTA Centessa Pharmaceuticals	3.00	Buy	$27.71	102.15% Upside
DNA Ginkgo Bioworks	1.60	Reduce	$4.58	-37.92% Downside
GLPG Galapagos	1.50	Reduce	$25.33	-5.89% Downside

Current Analyst Ratings Breakdown

Latest DNA, ARWR, CNTA, and GLPG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/31/2025	CNTA Centessa Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$38.00
3/26/2025	CNTA Centessa Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
3/7/2025	CNTA Centessa Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$27.00 ➝ $27.00
2/14/2025	ARWR Arrowhead Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$51.00 ➝ $38.00
2/14/2025	GLPG Galapagos	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Equal Weight ➝ Underweight	$31.00 ➝ $22.00
2/12/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
2/11/2025	ARWR Arrowhead Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$42.00 ➝ $42.00
2/11/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
2/10/2025	CNTA Centessa Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$2.50M	762.93	N/A	N/A	$1.54 per share	9.02
CNTA Centessa Pharmaceuticals	$6.85M	266.45	N/A	N/A	$2.42 per share	5.67
DNA Ginkgo Bioworks	$227.04M	1.88	N/A	N/A	$21.93 per share	0.34
GLPG Galapagos	$288.19M	6.16	N/A	N/A	$47.57 per share	0.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$5.17	N/A	N/A	N/A	N/A	-236.60%	-64.09%	5/8/2025 (Estimated)
CNTA Centessa Pharmaceuticals	-$151.09M	-$1.99	N/A	N/A	N/A	N/A	-52.13%	-38.01%	5/12/2025 (Estimated)
DNA Ginkgo Bioworks	-$892.87M	-$10.68	N/A	N/A	N/A	-298.78%	-58.54%	-34.24%	5/8/2025 (Estimated)
GLPG Galapagos	$80.16M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest DNA, ARWR, CNTA, and GLPG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	CNTA Centessa Pharmaceuticals	-$0.35	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	N/A	N/A	N/A	$116.27 million	N/A
5/8/2025	Q1 2025	DNA Ginkgo Bioworks	-$1.23	N/A	N/A	N/A	N/A	N/A
4/23/2025	Q1 2025	GLPG Galapagos	-$0.23	-$2.47	-$2.24	-$2.45	$72.22 million	$97.33 million
3/24/2025	Q4 2024	CNTA Centessa Pharmaceuticals	-$0.38	-$0.34	+$0.04	-$0.84	N/A	N/A
2/10/2025	Q1 2025	ARWR Arrowhead Pharmaceuticals	-$0.42	-$1.39	-$0.97	-$1.39	$19.05 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CNTA Centessa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DNA Ginkgo Bioworks	N/A	N/A	N/A	N/A	N/A
GLPG Galapagos	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	7.27	6.09	6.09
CNTA Centessa Pharmaceuticals	0.15	21.52	21.52
DNA Ginkgo Bioworks	N/A	5.79	5.79
GLPG Galapagos	N/A	9.97	9.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
CNTA Centessa Pharmaceuticals	82.01%
DNA Ginkgo Bioworks	78.63%
GLPG Galapagos	32.46%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
CNTA Centessa Pharmaceuticals	11.59%
DNA Ginkgo Bioworks	9.72%
GLPG Galapagos	2.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	137.32 million	120.68 million	Optionable
CNTA Centessa Pharmaceuticals	200	133.18 million	116.56 million	Optionable
DNA Ginkgo Bioworks	640	58.03 million	51.89 million	Optionable
GLPG Galapagos	1,310	65.90 million	63.98 million	Optionable

DNA, ARWR, CNTA, and GLPG Headlines

Recent News About These Companies

Galapagos Sees Unusually High Options Volume (NASDAQ:GLPG)

April 30 at 4:34 PM | marketbeat.com

Galapagos Target of Unusually Large Options Trading (NASDAQ:GLPG)

April 30 at 3:25 AM | americanbankingnews.com

Galapagos NV Announces Key Resolutions from Annual Shareholders’ Meeting

April 29 at 5:08 PM | tipranks.com

StockNews.com Downgrades Galapagos (NASDAQ:GLPG) to Sell

April 27, 2025 | americanbankingnews.com

RBC Capital Sticks to Their Hold Rating for Galapagos (GLPG)

April 26, 2025 | markets.businessinsider.com

Analysts Set Galapagos NV (NASDAQ:GLPG) Target Price at $25.33

April 26, 2025 | americanbankingnews.com

Galapagos: Targeting High Unmet Medical Need Of MCL Focus With GLPG5101

April 25, 2025 | seekingalpha.com

Galapagos NV (NASDAQ:GLPG) Given Average Rating of "Reduce" by Analysts

April 25, 2025 | marketbeat.com

Galapagos NV Reports Q1 2025 Results and Strategic Updates

April 25, 2025 | tipranks.com

Galapagos NV (GLPG) Q1 2025 Earnings Call Transcript

April 24, 2025 | seekingalpha.com

Uncovering Potential: Galapagos's Earnings Preview

April 24, 2025 | benzinga.com

Galapagos NV Reports Q1 2025 Results and Strategic Developments

April 23, 2025 | tipranks.com

Stoffels To Depart Galapagos, Short of Five-Year Mission To Remake the Biotech

April 23, 2025 | biospace.com

Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts

April 23, 2025 | globenewswire.com

Galapagos sources CEO for oncology spin-off as Stoffels plans exit

April 22, 2025 | thepharmaletter.com

XTX Topco Ltd Boosts Holdings in Galapagos NV (NASDAQ:GLPG)

April 22, 2025 | marketbeat.com

Galapagos Announces Executive Leadership Updates

April 21, 2025 | markets.businessinsider.com

Galapagos CEO Paul Stoffels to retire, Henry Gosebruch named CEO of SpinCo

April 21, 2025 | msn.com

16,707,477 Shares in Galapagos NV (NASDAQ:GLPG) Bought by Gilead Sciences Inc.

April 20, 2025 | marketbeat.com

Galapagos Stock Price, Quotes and Forecasts | NASDAQ:GLPG | Benzinga

April 18, 2025 | benzinga.com

Galapagos (GLPG) Expected to Announce Earnings on Wednesday

April 17, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNA, ARWR, CNTA, and GLPG Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$13.89 +0.42 (+3.12%)

As of 04/30/2025 04:00 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Centessa Pharmaceuticals NASDAQ:CNTA

$13.71 -0.01 (-0.07%)

As of 04/30/2025 04:00 PM Eastern

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Ginkgo Bioworks NYSE:DNA

$7.37 -0.01 (-0.14%)

As of 04/30/2025 03:59 PM Eastern

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Galapagos NASDAQ:GLPG

$26.92 0.00 (0.00%)

As of 04/30/2025 04:00 PM Eastern

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time